PsychedeLinks is a weekly digest of news, business, and culture in the psychedelics industry curated by members of Emerge Law Group’s groundbreaking Psychedelics Industry Group.
Oregon Psilocybin Services Act
The Use of Psilocybin is on the Ballot Again For Many Oregon Voters
Oregonians voted to legalize the use of the psychedelic drug psilocybin in supervised facilities in 2020. But 27 of the state’s 36 counties now have the issue on their ballots again. The vote will have implications for residents seeking treatment across the Pacific Northwest.
The Battle for Psilocybin Therapy
In November 2020, Oregonians voted on the Oregon Psilocybin Services Act, and it passed. Now, two years later, more than half of Oregon’s 36 counties, and many cities, are voting again. Meas…
Psilocybin Advocates Make Push as November Election Brings Local Efforts to Opt Out of Measure 109
For many Oregonians, magic mushrooms are on the ballot this November—again.
Campaign Launches as Jackson County Voters Set to Decide on Psilocybin Treatment
After Jackson County Commissioners moved to put on the ballot a measure to make psilocybin treatment illegal in unincorporated areas of Jackson County, a group of Southern Oregon veterans, organizations, and mental health providers have come together to campaign ‘no’.
Legalization, Decriminalization, & Other State Efforts
The Psychedelics Renaissance is Here - Colorado May Become the Second State in the Nation to Legalize Therapeutic Psychedelics
This November, Coloradans have opportunity to make history and vote for Colorado to become the second state in the country to regulate therapeutic...
Right To Try
DEA Faces New Legal Challenges Over Denying Psilocybin Rescheduling Petition And Doctor’s Federal Waiver Request
The Drug Enforcement Administration (DEA) has again rejected a petition to reschedule psilocybin and a doctor’s request for a federal waiver to obtain and administer the psychedelic to terminally ill patients, prompting a new set of legal challenges in federal court. Sunil Aggarwal, a Washington Sta…
Research, Therapy, & Science
NIH-Funded Psychedelic Trial Will Study Whether Hallucinogen Can Help Smokers Quit
Early research has found that psilocybin, the psychedelic compound found in “magic mushrooms,” helped smokers kick the habit.
How Psychedelics Light Up Brain’s Neuropathways
Study reveals the basic neurobiology of how psychedelics work at the chemical, molecular, neural, and network levels within the brain.
Manipulating Light Can Induce Psychedelic Experiences – And Scientists Aren’t Quite Sure Why
The most powerful technique is called ganzflicker and is similar to strobe lights.
Business
With Promise of Legalization, Psychedelic Companies Joust Over Future Profits
Cash rich start-ups are filing scores of patent claims on hallucinogens like magic mushrooms. Researchers and patient advocates worry high prices will make the therapies unaffordable.
Consolidation in Psychedelics starts as Beckley and Eleusis Combine
Psychedelic medicines company Beckley Psytech has reached an agreement to acquire its rival Eleusis Therapeutics, in alignment with predictions that the sector is heading for a period of consolidation.
World
Research, Remedy and Regulation: The Changing Dynamics of Psychedelic Therapy in Alberta
Earlier this month, Alberta announced new regulations for the use of psychedelics in therapy. Researchers and health-care professionals are increasingly exploring how drugs like ketamine can be used for mental health treatment.
Subscribe
Subscribe to PsychedeLinks to receive essential weekly articles on news, business, and culture in the psychedelics industry, delivered straight to your inbox.
PsychedeLinks by Emerge Law Group
PsychedeLinks is a weekly brief on news, business, and culture in the psychedelics industry curated by members of Emerge Law Group's groundbreaking Psychedelics Industry Group.
